Clinical Trial Update: Neladalkib (NVL-655) for TKI-naive Patients With Advanced ALK-Positive NSCLC [Phase 3]

View source ↗

Summary

A Phase 3 trial of neladalkib (NVL-655) for tyrosine kinase inhibitor–naive patients with advanced ALK-positive non-small cell lung cancer is currently recruiti…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Alk-positive Non-small Cell Lung Cancer
• Non-small Cell Lung Cancer

Drugs mentioned

• Neladalkib (neladalkib)

Snippet

Sponsor: Nuvalent Inc. | Conditions: Non-small Cell Lung Cancer, Anaplastic Lymphoma Kinase-positive | Phase 3 | Status: RECRUITING